Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875638 · ClinicalTrials.gov registry record · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
A Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT03875638: Recruiting Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Beth Israel Deaconess Medical Center.
NCT03875638 is a Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 85 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03875638, a Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic medication levetiracetam (LEV) normalizes these measures and improves cognition.
Primary Outcome
Our primary cognitive outcome measure will be the mean z-score change relative to baseline on the NTB
Conditions Studied
Interventions
- DRUG Levetiracetam
- DRUG Placebo oral capsule
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 2 |
What NCT03875638 shows while recruiting
NCT03875638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Levetiracetam is the first listed.
NCT03875638 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03875638 about?
NCT03875638 is a clinical study titled "Treating Hyperexcitability in AD With Levetiracetam". The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic medication levetiracetam (LEV) normalizes these measures and improves ...
What is the current status of trial NCT03875638?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2019-08-22. Estimated completion is 2025-11-30.
What conditions does trial NCT03875638 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia of Alzheimer Type, Alzheimer Dementia.
What interventions are being tested in trial NCT03875638?
The interventions under investigation include: Levetiracetam (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03875638?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03875638 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03875638's enrollment target sits among peer trials
85 165th of 306 higher than 142 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03896529 · 85 participants · NA
Neurobiological Mechanisms of Aging and Stress on Prospective Navigation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI